|Awarded On||August 24, 2018|
|Title||Targeting MYCN-Driven Metabolism in Neuroblastoma|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Eveline Barbieri|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
Neuroblastoma (NB) accounts for 15% of all pediatric cancer deaths. The majority of patients which present with amplification of the oncogene MYCN die due to drug-resistant disease relapse. Thus, strategies that disrupt MYCN oncogenic programming are critically needed for NB therapy. Cell metabolism, or the way in which cells use nutrients, is a key aspect of tumor biology. Tumors frequently have alterations, or undergo rewiring, in the specific type of nutrients they require for growth. In particular, MYCN is capable of driving defined changes in tumor metabolism. We have recently discovered a novel approach to oppose these metabolic changes driven by MYCN in NB. Our approach relies on re...